Oramed Pharmaceuticals Inc.
General ticker "ORMP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $108.9M (TTM average)
Oramed Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 55.1%.
Estimated limits based on current volatility of 3.0%: low 3.65$, high 3.88$
Factors to consider:
- Company pays dividends (irregularly): last record date 2026-01-16, amount 0.25$ (Y6.85%)
- Total employees count: 15 (-11.8%) as of 2023
- Top business risk factors: Strategic risks and growth management, Labor/talent shortage/retention, Operational and conduct risks, Third-party risks, Market competition
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.10$, 3.89$]
- 2026-12-31 to 2027-12-31 estimated range: [2.20$, 4.05$]
Financial Metrics affecting the ORMP estimates:
- Positive: with PPE of 3.6 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 4.45 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 86.52 > 64.29
- Negative: negative Industry operating cash flow (median)
Short-term ORMP quotes
Long-term ORMP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.34MM | $0.00MM | $2.00MM |
| Operating Expenses | $17.11MM | $12.78MM | $17.09MM |
| Operating Income | $-15.77MM | $-12.78MM | $-15.09MM |
| Non-Operating Income | $20.86MM | $-3.14MM | $90.41MM |
| Interest Expense | $2.04MM | $0.85MM | $0.00MM |
| R&D Expense | $8.97MM | $6.32MM | $6.38MM |
| Income(Loss) | $5.09MM | $-15.92MM | $75.32MM |
| Taxes | $0.00MM | $3.18MM | $11.31MM |
| Net Income(Loss)* | $5.53MM | $-19.06MM | $64.05MM |
| Stockholders Equity | $163.82MM | $146.26MM | $199.74MM |
| Assets | $220.55MM | $155.28MM | $230.86MM |
| Operating Cash Flow | $-10.29MM | $-8.41MM | $-9.14MM |
| Capital expenditure | $0.25MM | $0.02MM | $1.93MM |
| Investing Cash Flow | $-73.04MM | $105.82MM | $5.44MM |
| Financing Cash Flow | $51.98MM | $-52.04MM | $-4.74MM |
| Earnings Per Share** | $0.14 | $-0.47 | $1.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.